HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Nanotech Guidance Draws Industry Comment On Particle Size Criteria

This article was originally published in The Rose Sheet

Executive Summary

FDA's draft guidance to industry suggesting that ingredients up to 1 micrometer in size still qualify as nanomaterials if they exhibit “altered properties” should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.

You may also be interested in...



REACH Data Requirements For Nanoform Substances Just Got Stiffer

Manufacturers and importers of nanoform substances must meet new REACH information requirements by Jan. 1, 2020, under a regulation adopted by the European Commission Dec. 3. The European Chemicals Agency is considering issuing guidance to support industry’s compliance efforts.

Existing Safety Principles Suffice For Nano-Cosmetics Evaluation – FDA

FDA maintains that the current framework for cosmetic safety assessment is sufficient to control potential risks associated with nano-engineered cosmetics. However, traditional testing methods may need to be modified or new strategies developed to account for nanomaterials’ unique properties and behavior, the agency says in final guidance issued June 24.

FDA Advisors Want More Data On Nanotech Sunscreens

Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s understanding of how pharmaceutical firms are using nanotechnology is still developing, but they maintain that currently marketed products are safe.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel